Publication | Closed Access

Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin–angiotensin–aldosterone system inhibition

UrologyRenal DiseaseRenal FunctionDiabetesChronic Kidney DiseaseRenal InflammationPharmacologyType 2Diabetic Kidney DiseaseRenin–angiotensin–aldosterone System InhibitionRenal PathophysiologyMedicineRenal PharmacologyNephrologyOral Cholecalciferol